Biohit Oyj

Share Issue/Capital Change • Aug 7, 2015

Biohit Oyj B-shares Subscribed with Stock Options I 2013 B

Biohit Oyj B-shares Subscribed with Stock Options I 2013 B

Biohit Oyj Stock Exchange Release August 7, 2015 at 9:30 a.m. local time (EEST)

A total number of 32,940 new Biohit Oyj B-shares have been subscribed for with
stock options I 2013 B during July 7th, 2015. These shares have been entered
into the trade register on August 7th, 2015, as of which date the new shares
will establish equal shareholder rights with the company's existing B-shares.
Public trading is expected to begin on NASDAQ OMX Helsinki as of August 10,
2015 together with the existing B-shares.

The share subscription price was EUR 2.2766 per share respectively. The entire
subscription price of EUR 74,991.20 will be credited to the reserve for
invested non-restricted equity, and the company share capital remains
unchanged. The shares have no nominal value.

After the subscription the number of all Biohit Oyj's shares will rise to
14,348,533 shares (14,315,593) and B-shares will rise to 11,373,033 shares
(11,340,093). The new shares will correspond to a percentage of 0.23% of Biohit
Oyj's total number of shares and 0.05% of the voting rights after registration.

The share subscription period with stock options I 2013 B began on June 1, 2015
and will end May 31, 2019 and 32,940 of the available 40,000 shares were
subscribed. The option schemes are based on the Biohit Oyj board resolution of
June 19, 2013 and the Annual General Meeting authorization of April 14, 2014.
The terms and conditions of the option schemes with additional information are
available on Biohit Oyj website at www.biohithealthcare.com.

Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com